AMNEAL PHARMACEUTICALS, INC. $AMRX Shares Bought by PDT Partners LLC

Key Points

• PDT Partners LLC significantly increased its stake in Amneal Pharmaceuticals by 200.7%, acquiring an additional 158,900 shares in the 1st quarter, bringing its total ownership to 238,069 shares valued at nearly $2 million.
• Multiple institutional investors, including Vanguard Group and Invesco, have also raised their positions in Amneal Pharmaceuticals, which is currently 31.82% owned by institutional investors.
• Amneal Pharmaceuticals reported $0.23 earnings per share for the last quarter, exceeding estimates, and has set a guidance for FY 2025 of 0.700-0.750 EPS.

PDT Partners LLC boosted its holdings in shares of AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) by 200.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 238,069 shares of the company's stock after purchasing an additional 158,900 shares during the period. PDT Partners LLC owned about 0.08% of AMNEAL PHARMACEUTICALS worth $1,995,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMRX. Sei Investments Co. raised its position in shares of AMNEAL PHARMACEUTICALS by 0.4% in the first quarter. Sei Investments Co. now owns 340,816 shares of the company's stock worth $2,710,000 after acquiring an additional 1,355 shares during the period. Amalgamated Bank raised its position in shares of AMNEAL PHARMACEUTICALS by 33.0% in the first quarter. Amalgamated Bank now owns 5,511 shares of the company's stock worth $46,000 after acquiring an additional 1,367 shares during the period. GF Fund Management CO. LTD. raised its position in shares of AMNEAL PHARMACEUTICALS by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 7,934 shares of the company's stock worth $66,000 after acquiring an additional 1,428 shares during the period. Xponance Inc. raised its position in shares of AMNEAL PHARMACEUTICALS by 16.1% in the first quarter. Xponance Inc. now owns 13,183 shares of the company's stock worth $110,000 after acquiring an additional 1,828 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of AMNEAL PHARMACEUTICALS by 3.3% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 90,460 shares of the company's stock worth $716,000 after acquiring an additional 2,911 shares during the period. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. The Goldman Sachs Group initiated coverage on shares of AMNEAL PHARMACEUTICALS in a research report on Friday, June 6th. They set a "buy" rating and a $12.00 price target for the company. Wall Street Zen cut AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $11.60.

Insider Buying and Selling

In other news, Director John Kiely sold 32,000 shares of the company's stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $9.23, for a total value of $295,360.00. Following the completion of the sale, the director directly owned 225,433 shares of the company's stock, valued at approximately $2,080,746.59. This represents a 12.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jason B. Daly sold 22,000 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total transaction of $199,100.00. Following the completion of the sale, the executive vice president directly owned 10,606 shares of the company's stock, valued at $95,984.30. The trade was a 67.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 609,206 shares of company stock worth $5,700,625. 26.56% of the stock is owned by corporate insiders.

AMNEAL PHARMACEUTICALS Stock Up 0.7%

Shares of AMNEAL PHARMACEUTICALS stock traded up $0.07 during mid-day trading on Friday, hitting $9.62. The stock had a trading volume of 1,273,897 shares, compared to its average volume of 1,583,692. The firm has a 50-day moving average of $8.67 and a two-hundred day moving average of $8.13. The firm has a market cap of $3.02 billion, a P/E ratio of 962.96 and a beta of 1.19. AMNEAL PHARMACEUTICALS, INC. has a 12-month low of $6.68 and a 12-month high of $9.79.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a net margin of 0.12% and a negative return on equity of 189.49%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. Sell-side analysts expect that AMNEAL PHARMACEUTICALS, INC. will post 0.53 earnings per share for the current year.

About AMNEAL PHARMACEUTICALS

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.